VCM
ARKG icon

Viewpoint Capital Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Viewpoint Capital Management’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,178
Closed -$72K – 116
2022
Q3 		$72K Hold
2,178
– – 0.07% 91
2022
Q2 		$69K Hold
2,178
– – 0.06% 97
2022
Q1 		$100K Hold
2,178
– – 0.08% 97
2021
Q4 		$133K Buy
+2,178
New +$151K 0.1% 97

Other funds holding ARKG

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Viewpoint Capital Management's ARKG Position: Q4 2022 in Review

Viewpoint Capital Management sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2022, closing a stake of 2,178 shares — an estimated $72K sold.

Viewpoint Capital Management first reported a position in ARKG in Q4 2021 and held it in 4 quarters. The position peaked at $133K in Q4 2021. 319 funds tracked by Wall St. Rank hold ARKG as of Q4 2022.

  • Viewpoint Capital Management reported no remaining ARK Genomic Revolution ETF position as of Q4 2022 after selling out during the quarter.
  • Viewpoint Capital Management sold 2,178 ARK Genomic Revolution ETF shares in Q4 2022, an estimated $72K.
  • Viewpoint Capital Management first reported a position in ARK Genomic Revolution ETF in Q4 2021 and held it in 4 quarters.
  • Viewpoint Capital Management's ARK Genomic Revolution ETF position peaked at $133K in Q4 2021.
  • 319 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2022.

Based on Viewpoint Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.